Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma

BACKGROUND: No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Kaley, Thomas J., Wen, Patrick, Schiff, David, Ligon, Keith, Haidar, Sam, Karimi, Sasan, Lassman, Andrew B., Nolan, Craig P., DeAngelis, Lisa M., Gavrilovic, Igor, Norden, Andrew, Drappatz, Jan, Lee, Eudocia Quant, Purow, Benjamin, Plotkin, Scott R., Batchelor, Tracy, Abrey, Lauren E., Omuro, Antonio
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483051/
https://ncbi.nlm.nih.gov/pubmed/25100872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou148
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados